The Goodwin Life Sciences team advised Prime Medicine on its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.
The Goodwin team was led by Kingsley Taft, Marishka DeToy, Karin Yoo, Haylee Brown and Sari Lerner, and included Julie Tibbets (FDA), Heath Ingram (Healthcare), Michael Shuster (Intellectual Property), Dan Karelitz (Tax), and Brad Weber (Opinions).
For more information on the offering, please read the press release.